top of page



Cellular Matrix from Regenlab is a patented and modern injection treatment where PRP (platelet-rich plasma) is combined with Hyaluronic acid in the same injection. As a patient, you will achieve a great reduction in pain, less fluid formation and an increased quality of life with mild to moderate osteoarthritis. The effect will give the patient the opportunity to resume training and activities that were previously painful or impossible.


Cellular Matrix ® from RegenLab, is a mixture of A-PRP with Hyaluronic acid, which is intended for the treatment of mild to moderate osteoarthritis. The product is produced by centrifuging a 10ml venous blood sample in a container containing a patented separation gel, anticoagulant and Hyaluronic acid. CellularMatrix is then injected intra-articularly into the joint.

Hyaluronic acid is an important component of connective tissue and is, among other things, responsible for pressure absorption in joints. The composition of PRP and HA in Cellular Matrix should lubricate the joint and optimize cartilage and tissue through HA capacity to bind fluid and thus PRP. This will have the best effect in patients with mild to moderate osteoarthritis. Several recent studies (2019) could prove that Cellular matrix (PRP-HA) had a significantly better effect on both pain and functionality in patients with osteoarthritis than hyaluronic acid alone. RegenLab has FDA and CE approval, and over 2 million patients have been treated with their PRP systems in the USA, Europe and Asia. 


Ny French multicenter study shows that 87% of patients with knee arthrosis who previously had little benefit from HA alone, received significant pain reduction and strong functional improvement.  Cellular Matrix ® contains an anticoagulant (sodium citrate, PH7, isotonic ), so that the product can be prepared and injected at its own pace, without worrying about the liquid coagulating. The anticoagulant ensures that the coagulation process is delayed for 1-2 hours, which gives the practitioner plenty of time for the procedure.


The combination of separation gel and anticoagulant ensures a stable product, where each injection is the same. In addition, Cellular Matrix ® is a closed product that cannot be contaminated from the outside. This provides additional safety for the patient. Newer studies with Cellular Matrix   show a positive effect on the treatment of mild to moderate arthrosis.




Cellular matrix is used in cases of mild to moderate osteoarthritis. The whole process of making this is similar to A-PRP. The only difference is that 2ml of hyaluronic acid has been added to these tubes. Note that cellular matrix is not recommended, but rather A-PRP if the patient is allergic or hypersensitive to hyaluronic acid.



OA grade 1: 

1 injection per treatment. During follow-up after 6 months, a new dose can be injected. If the knee is full of fluid, it is recommended to aspirate this beforehand.  


OA grade 2-3: 

1 injection every month for 3 months for optimal results.


OA grade 4: 

1 injection every month for 3 months. A follow-up injection after 6 months if necessary.  This is the only preparation that allows the combination of PRP and hyaluronic acid (HA) in relation to CE laws and regulations. Considering that it is not allowed to modify medicine or biological drugs, the user/therapist cannot mix this himself.   


Biology PRP is prepared in a composition with high quality, non-cross linked HA which is produced through a bacterial fermentation. HA creates a cell-friendly environment where platelets can aggregate. This biological, composite network of PRP and HA facilitates cell migration and cell spread in the injected area. HA ensures viscoelasticity, increases the effect of and stabilizes the growth factors in PRP.

It has the capacity to bind up to 1000x the amount of water of its own volume. HA is very well suited in the treatment of OA, while it has also been proven that the effect of HA is not long-lasting. Therefore, the combination of PRP and HA is the best, because PRP will optimize the tissue and HA ensures that the conditions for this are as favorable as possible.

The catabolic process of inflammation and degeneration that induces pain and stiffness is reversed to regulate inflammation and relieve symptoms. PRP and HA have a good effect on symptomatic joint pain and on mobility. There is considerable evidence that the synergy between these two is exclusively positive. There are several studies that have researched the connection between PRP and HA. See more information under our documents or contact Adcare.


After treatment Rest is recommended for the first 24 hours after treatment. The patient must not engage in sports/exercise or other activities that put a high strain on the injured area, and must avoid activities beyond normal, daily tasks. The patient may experience that the discomfort at the site of the injury increases slightly for the first 48 hours, but that this will decrease thereafter. NSAIDs must not be used. 

Results Arthrosis Treatment of arthrosis in the knee, hip and shoulder. A number of published studies. A-PRP/HA treatment with Cellular Matrix resulted in a positive symptomatic effect. A-PRP/HA has been shown to be noticeably more effective than Hyaluronic Acid. "CellularMatrix provided significant pain relief and functional improvement in 87.3% of patients who had an unsatisfactory clinical response to previous therapy with HA alone. Renevier JL, Marc JF, Revue du Rhumatisme 2014;81:A202

Please contact us for more information about the injection.



A-PRP for the treatment of sports-related injuries. Autologous platelet-rich plasma (PRP) is a form of treatment where the bodys own platelets are separated and used to start a more effective healing process for injuries to tendons, ligaments and muscles. Using a patented technique, red and white blood cells are separated and you are left with platelet-rich plasma or platelets with growth factors.


Description Platelet-enriched plasma (PRP) is a good alternative for treating soft tissue (tendinopathies, meniscus, muscle tears, etc.) in the musculoskeletal system. In Norway, interest in PRP is growing and Adcare is a distributor of A-PRP® (Autologous platelet-rich plasma) from the company RegenLab. RegenLab has FDA and CE approval, and over 2 million patients have been treated with their A-PRP system in the USA, Europe and Asia.



A-PRP from RegenLab A-PRP A-PRP® is platelet-enriched plasma and platelet concentrate with an extremely low level of red and white blood cells, produced from the patient&s own blood. A venous blood sample of 10ml is centrifuged in a container containing a patented separation gel that creates a barrier against the red/white blood cells. The gel, which is in solid form, will change its structure to liquid during centrifugation, so that it settles between the substances (plasma, platelets, lymphocytes, monocytes and mesenchymal cells) and the substances ( red blood cells, ergocytes and granulites) after centrifugation.


Red blood cells will be reduced by 99.7%. The white blood cells will be reduced by 96.7% and what little is left are the anti inflammatory white blood cells; lymphocytes and monocytes. This ensures that you have a finished A-PRP® with active platelets, which is the purest possible and with the markets lowest leukocyte level. The platelets are platelet enriched with a concentration of 1.6 times and at least 80% of the platelets are preserved in the sample in addition to growth factors such as FGF, PDGF, TGF-ß, EGF, VEGF and IGF. The finished product will provide 5-6ml of solution for the injection. A-PRP stimulates vascularization at the site of injury and optimal tissue regeneration.



A-PRP is mainly used only on soft tissue (tendinopathies, meniscus, muscle tears, etc.).

The exception is in patients who are allergic/hypersensitive to hyaluronic acid. Already on the same day that the injury occurs, you can inject. The earlier, the better. For sports injuries, 1 injection is usually enough. The use of A-PRP on soft tissue injuries has been proven to shorten the healing process by 40-50% and to reduce pain

bottom of page